A Small Molecule Screen Identifies Selective Inhibitors of Urea Transporter UT-A  by Esteva-Font, Cristina et al.
Chemistry & Biology
ArticleA Small Molecule Screen Identifies
Selective Inhibitors of Urea Transporter UT-A
Cristina Esteva-Font,1 Puay-Wah Phuan,1 Marc O. Anderson,2 and A.S. Verkman1,*
1Departments of Medicine and Physiology, University of California, San Francisco, San Francisco, CA 94143-0521, USA
2Department of Chemistry and Biochemistry, San Francisco State University, San Francisco, CA 94132-4136, USA
*Correspondence: alan.verkman@ucsf.edu
http://dx.doi.org/10.1016/j.chembiol.2013.08.005SUMMARY
Urea transporter (UT) proteins, including UT-A in kid-
ney tubule epithelia and UT-B in vasa recta micro-
vessels, facilitate urinary concentrating function. A
screen for UT-A inhibitors was developed in MDCK
cells expressing UT-A1, water channel aquaporin-1,
and YFP-H148Q/V163S. An inwardly directed urea
gradient produces cell shrinking followed by UT-A1-
dependent swelling, which was monitored by YFP-
H148Q/V163S fluorescence. Screening of 90,000
synthetic small molecules yielded four classes of
UT-A1 inhibitors with low micromolar half-maximal
inhibitory concentration that fully and reversibly
inhibited urea transport by a noncompetitive mech-
anism. Structure-activity analysis of >400 analogs
revealedUT-A1-selective andUT-A1/UT-B nonselec-
tive inhibitors. Docking computations based on ho-
mologymodels of UT-A1 suggested inhibitor binding
sites. UT-A inhibitors may be useful as diuretics
(‘‘urearetics’’) with a mechanism of action that may
be effective in fluid-retaining conditions in which
conventional salt transport-blocking diuretics have
limited efficacy.
INTRODUCTION
Urea is important in mammalian physiology because it is the end
product of nitrogen metabolism and required for normal kidney
function. The generation of a concentrated urine by the kidney
involves a countercurrent multiplication mechanism, which is
facilitated by aquaporins, a Na+/K+/2Cl- cotransporter (NKCC2)
in the thick ascending limb of Henle, and urea transporters
(UTs) in tubule epithelial cells and in microvascular (vasa recta)
endothelia (Bankir and Yang, 2012; Fenton, 2009; Lei et al.,
2011; Pannabecker, 2013; Sands 2007). Loss of UT function is
predicted to disrupt urinary concentrating ability (Fenton et al.,
2004; Sands and Layton, 2009), and hence UTs are potential
targets for the development of diuretics (‘‘urearetics’’) with a
distinct mechanism of action and clinical indication profile.
Kidney tubule epithelial cells express UT-A isoforms, encoded
by the SLc14A2 gene; and kidneymicrovascular endothelial cells
(in vasa recta) express UT-B, encoded by the SLc14A1 gene
(Bagnasco, 2003; Doran et al., 2006; Fenton et al., 2002; Shaya-Chemistry & Biology 20, 1235–1kul et al., 2013; Tsukaguchi et al., 1997). The UT-A gene family
contains at least six isoforms, generated by alternative splicing,
with the largest isoform being UT-A1 (Shayakul and Hediger,
2004; Smith, 2009; Stewart, 2011). UT-A1 and UT-A3 are ex-
pressed in the kidney inner medullary collecting duct, and UT-
A2 in the thin descending limb of Henle in both inner and outer
medulla (Fenton, 2009; Klein et al., 2012; Pannabecker, 2013;
Sands, 2004). Knockout mice lacking both UT-A1 and UT-A3
manifest a marked urinary concentrating defect (Fenton et al.,
2004, 2005; Fenton, 2008). However, urinary concentrating func-
tion is largely unimpaired in UT-A2 knockout mice (Uchida et al.,
2005) and in UT-A1/A3 knockout mice after transgenic replace-
ment of UT-A1 (Klein et al., 2013), suggesting UT-A1 as the prin-
cipal UT-A family target for inhibitor development. Knockout
mice lacking UT-B (Yang et al., 2002; Yang and Verkman,
2002), and rare humans with loss of function mutations in UT-B
(the erythrocyte JK antigen) manifest a relatively mild urinary
concentrating defect (Lucien et al., 1998; Sands et al., 1992).
Until recently, available UT inhibitors included the nonselective
membrane intercalating agent phloretin and millimolar potency
urea analogs (Mayrand and Levitt, 1983). Our lab identified nano-
molar affinity, small-molecule UT-B inhibitors using an erythro-
cyte lysis-based high-throughput screen (Levin et al., 2007).
Erythrocytes express UT-B and are highly water permeable
because they also express aquaporin-1 (AQP1) water channels.
Erythrocyte lysis, as measured by infrared light absorbance, was
used as a read-out of UT-B function following creation of an
outwardly directed gradient of acetamide, a UT-B substrate
with optimal transport properties for screening. Our original phe-
nylsulfoxyoxozole UT-B inhibitors had a half-maximal inhibitory
concentration (IC50) of 100 nM for human UT-B, although
they had much lower inhibition potency for rodent UT-B, pre-
cluding testing in rodent models (Anderson et al., 2012; Yao
et al., 2012). A subsequent screen done using mouse erythro-
cytes identified triazolothienopyrimidines as UT-B inhibitors
with an IC50 25 nM for mouse UT-B and 10 nM for human
UT-B (Yao et al., 2012). The triazolothienopyrimidines had high
selectivity for UT-B over UT-A, and they reduced urinary concen-
tration in mice to that in UT-B knockout mice. However, the
effect of UT-B inhibition or genetic deletion is modest—based
on knockout mouse data and computational models UT-A is
predicted to be substantially more important in urinary concen-
trating function. Recently, a thienoquinoline class of UT-B inhib-
itors was reported, albeit with relatively low inhibition potency (Li
et al., 2013).
The purpose of this study was to identify UT-A1 inhibitors. We
developed a robust cell-based high-throughput screen that was244, October 24, 2013 ª2013 Elsevier Ltd All rights reserved 1235
Figure 1. Development and Validation of UT-A1 Inhibitor Screen
(A) Assay method. MDCK cells stably expressing UT-A1, AQP1, and YFP-H148Q/V163S are subjected to a 800-mM urea gradient. A rapid decrease of the cell
volume (reduced fluorescence) due to the water efflux through AQP1 is followed by cell re-swelling (increased fluorescence) due to urea and water. The UT-A1
inhibitor phloretin alters curve shape.
(B) UT-A1 and AQP1 immunofluorescence of the triply transfected cells, shown with YFP fluorescence.
(C) YFP fluorescence kinetics in response to an 800-mM urea gradient in cells expressing YFP-H148Q/V163S alone and together with UT-A1 and/or AQP1.
(D) Effects of prior UT-B inhibitors ureainh-302 (Levin et al., 2007) and UTBinh-14 (Yao et al., 2012) on UT-A1 urea transport. In this and subsequent data, curves
shown in green and red represent control (no inhibitor) and full inhibition (phloretin), respectively.
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structure-activity analysis, compounds were identified with
high UT-A1 selectivity, as well as nonselective compounds
with similar UT-A1 and UT-B inhibition potency. Inhibition mech-
anisms were characterized and molecular docking computa-
tions were done to identify putative binding sites.
RESULTS
Development and Validation of UT-A1 Inhibitor Screen
The UT-A1 assay developed for high-throughput screening
involved measurement of cell volume changes in response to a
rapidly imposed gradient of urea in MDCK cells stably express-
ing UT-A1 (Figure 1A). Cell volume was followed using the
chloride-sensing, genetically encoded fluorescent protein YFP-
H148Q/V163S, which was developed previously for chloride
channel screening (Galietta et al., 2001). Changes in cell volume
alter intracellular chloride concentration, producing a near-
instantaneous change in YFP fluorescence. The cells were also
transfected with water channel AQP1 to ensure much higher
water than urea permeability. Rapid addition of urea to the extra-1236 Chemistry & Biology 20, 1235–1244, October 24, 2013 ª2013 Ecellular solution drives osmotic water efflux and cell shrinking,
which is followed by urea (and water) entry with return to the
original cell volume. A urea concentration gradient of 800 mM
was chosen empirically to produce a robust fluorescence signal
for screening.
Original data from 96-well plates are shown in Figure 1A
(center), in which error bars indicate theminimal well-to-well vari-
ability. We found that UT-A1-facilitated urea transport in trans-
fected MDCK cells grown on plastic did not require a cAMP
agonist, in contrast to results for filter-grown, fully polarized
MDCK cells (see below). Figure 1B shows UT-A1 and AQP1
immunofluorescence, along with cytoplasmic YFP fluorescence
in the transfected cells.
Data from cells transfected with YFP alone, and YFP together
with UT-A1 and/or AQP1 are shown in Figure 1C. Urea addition in
the triply transfected cells (upper left) produced rapid cell shrink-
ing and consequent reduced fluorescence, which was followed
by UT-A1-facilitated cell swelling and fluorescence increase.
Inhibition by phloretin produced a greater initial fluorescence
decrease and slowed recovery, similar to that in cells expressing
YFP and AQP1 (without UT-A1, lower left). In the absence oflsevier Ltd All rights reserved
Figure 2. UT-A1 Inhibitor Identification by
High-Throughput Screening
(A) Screening assay (left). YFP fluorescence
curves from ten negative (vehicle control) and ten
positive (full inhibition with phloretin) wells (right).
(B) Examples of compounds from primary
screening showing 0%, 50%, and 100% inhibi-
tion of UT-A1 urea transport.
(C) Summary of percentage UT-A1 inhibition by
25,000 compounds from the primary screen.
Twenty replicates of negative and positive con-
trols shown at the right.
(D) Summary of findings of the primary screen.
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slower (upper right), with UT-A1 reducing the fluorescence signal
because of the comparable rates of water and urea transport in
these cells. The fluorescence decrease was slow and phloretin-
independent in cells expressing YFP alone (lower right).
The assaywas applied to test UT-A inhibition by twopreviously
identified UT-B inhibitors, the phthalazinamine ureainh-302 and
the triazolothienopyrimidine UTBinh-14. Figure 1D shows dose-
response data with IC50 for inhibition of UT-A1-facilitated urea
transport of 16 mM for ureainh-302, in agreement with 15 mM
determined previously using a transepithelial transport assay
(Levin et al., 2007). A very high concentration of UTBinh-14 did
not inhibit UT-A1-facilitated urea transport, in agreement with
prior data showing very high UT-B selectivity (Yao et al., 2012).
Identification of UT-A1 Inhibitors by High-Throughput
Screening
The screening assay is diagrammed in Figure 2A, in which cells
were incubated with test compounds (25 mM) for 15 min at
37C, and then subjected to an 800 mM urea gradient during
continuous measurement of YFP fluorescence. Figure 2A (right)
shows data from ten individual wells for the negative control
(DMSO vehicle alone) and positive control (phloretin). Robust
differences were seen, with whole-plate Z0-factors generally
greater than 0.55.
Figure 2B provides examples of active and inactive com-
pounds from the primary screen, showing compounds that
have0%, 50%, and 100% inhibition. Figure 2C shows the per-
centage inhibition of urea transport inhibition for 25,000 com-
pounds from the primary screen, with the dashed line (at 90%
inhibition) indicting the criterion to select active compounds.
Results from a screen of 90,320 small synthetic compounds
are summarized in Figure 2D, which produced four chemical
classes of UT-A1 inhibitors, three of which (classes A, B and C,
see below) are new and one of which (class D) was identified
previously in a UT-B inhibitor screen (Yao et al., 2012).
Structure-Activity Analysis of UT-A1 Inhibitors
The structures of the most potent UT-A1 inhibitors emerging
from structure-activity studies are shown in Figure 3. A total of
106, 96, 27, and 200 commercially available analogs of classChemistry & Biology 20, 1235–1244, October 24, 2013 ªA, B, C, and D inhibitors, respectively,
were tested; data for the most potent
compounds of each class are summa-rized in Table 1. Original concentration-inhibition curves are
shown, in which increasing compound concentrations produce
greater inhibition, with 100% inhibition at high concentrations
as judged by comparison with the phloretin data.
Compound selectivity for inhibition of UT-A1 versus UT-B was
studied. As diagrammed in Figure 4A, a previously validated UT-
B inhibition assay was used involving optical measurement of
hypotonic lysis of acetamide-loaded erythrocytes following their
rapid dilution into acetamide-free buffer (Levin et al., 2007). Fig-
ure 4B shows dose-response data for UT-A1 and UT-B inhibition
for the best UT-A1 inhibitors of each class. UTA1inh-C1 showed
high UT-A1 selectivity whereas UTA1inh-B1 was nonselective.
IC50 values for UT-A1 and UT-B inhibition are summarized in
Table 1. Selectivity data for selected analogs are summarized
in Figure 4C. Interestingly, a large range of selectivities was
found, even for the same compound class, with some com-
pounds showing high UT-A1 or UT-B selectively, while others
with little selectivity.
Structure-activity data for UT-A1 and UT-B inhibition provided
information about the structural determinants for inhibitor activity.
Figure 4D summarizes the findings for class A inhibitors, the 8-
hydroxyquinolines (8-HQ). Unsubstituted 8-HQ analogs (top)
were UT-A1 selective. Their inhibition potency depended on the
R1 substituent, with benzylamine-bearing electron-donating
group such as methoxy giving the best UT-A1 inhibition activity.
Reduced activity was found with electron-withdrawing groups
such as halides. Unsaturated cyclic rings (piperazines and
cyclopentanamine) at R1 also reduced inhibition activity. Aniline-
substituted 8-HQ (bottom) were relatively nonselective, depend-
ing on the nature and position of the substituent on the aniline
ring, with 3,4-di-substituted anilines with electron-donating and/
or neutral substituent (such as methoxy, ethoxy, or methyl) giving
goodUT-A1 inhibition. Mono-substitution with an alkoxy group at
the 4-position on the aniline gave 8-HQs that inhibit both UT-A1
and UT-B (for example, UTA1inh-A1 and UTA1inh-A3 in Table 1).
Br substituents and Cl substituents on the aniline are tolerated,
whereasdi- or tri-substitutionson the aniline ring reducedactivity.
UT-A1 Inhibition Mechanism
UT-A1 inhibition by compounds in each of the four classes was
fully reversible. Cells were incubated with inhibitor for 15 min,2013 Elsevier Ltd All rights reserved 1237
Figure 3. UT-A1 Inhibitors Identified in the Screen
Chemical structures of UT-A1 inhibitors (UTA1inh-xx, with xx the identifying code) of each of four chemical classes (top). Concentration-inhibition data for each
inhibitor are shown (bottom).
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washing (Figure 5A).
The urea concentration dependence of UT-A1 inhibition was
studied by inhibition measurements done using different urea
concentrations. Figure 5B (left) shows comparable percentage
of UT-A1 inhibition for UTA1inh-A1 using 800, 400, and 200 mM
urea gradients. The deduced IC50 over a wide range of urea con-
centrations from 200 to 1,600 mM (Figure 5B, right) showed little
effect of urea gradient size for UTA1inh-A1, UTA1inh-B1, and
UTA1inh-C1, indicating a noncompetitive inhibition mechanism
and an 2.5-fold increase in IC50 for UTA1inh-D1, suggesting a
competitive inhibition mechanism.
The kinetics of UT-A1 inhibition was determined by assay of
UT-A1 inhibition at different times after compound addition. Fig-
ure 5C (left) shows YFP fluorescence curves after addition of
3 mM UTA1inh-B1 and UTA1inh-C1, showing that inhibition by
UTA1inh-B1 occurred over minutes whereas UTA1inh-C1
occurred within the time resolution of the measurement. Kinetic
data for each compound are summarized in Figure 5C (right).
These results suggest an extracellular site of action for
UTA1inh-C1, and an intracellular site of action for the class A,
B, and D compounds. We previously reported that the UT-B
selective class D analog UTBinh-14 had an intracellular site of
action in erythrocytes (Yao et al., 2012).
To verify UT-A1 inhibition using an independent assay that
does not rely on water transport or fluorescent indicators, we
measured UT-A1 facilitated urea transport in UT-A1-transfected
MDCK cells on porous filters in which the kinetics of urea accu-
mulation on the apical side was measured by enzymatic assay
following addition of urea to the basal side of the filter (Figure 5D).
UT-A1-facilitated urea transport in this system required a cAMP
agonist forskolin and was inhibited by phloretin. Each of the
compounds strongly inhibited UT-A1 urea transport.
Docking Computations
Homology modeling and computational docking studies were
done to investigate potential inhibitor binding sites and bound1238 Chemistry & Biology 20, 1235–1244, October 24, 2013 ª2013 Econformations. While a high-resolution X-ray crystal structure
of UT-A1 has not been reported, recently a structure of the
homologous bovine UT-B bound to selenourea was solved at
2.5 A˚ (Protein Data Bank [PDB] 4EZD; Levin et al., 2012), allowing
for the generation of a homology model of rat UT-A1. Potential
inhibitor binding sites in the cytoplasmic and extracellular pore
regions of UT-A1 were identified. Based on kinetic measure-
ments in Figure 5C, UTA1inh-A1 and UTA1inh-B1 were docked
to the cytoplasmic pore region of UT-A1 (Figures 6A and 6B),
andUTA1inh-C1was docked to the extracellular pore (Figure 6C).
Ligand and protein preparation, as well as docking simulations,
were performed with the OpenEye Scientific suite of utilities,
including the software FRED (v2.2.5; McGann, 2011). In the
bovine UT-B structure, two binding sites were identified for the
urea analog selenourea (adjacent to Thr334 and Thr172), which
correspond to analogous sites in the central channel of our rat
UT-A1 homology model. The cytoplasmic inhibitor binding site
is surrounded by Leu652, Leu895, Glu572, Ser700, and Phe832,
while the extracellular inhibitor binding site is surrounded by
Leu816, Phe814, Phe667, Leu734, Ala737, and Pro808. The majority
of neighboring residues are hydrophobic, and the presence of
Glu and Ser in the cytoplasmic binding site may provide an
opportunity for structure-based optimization. While quantitative
binding information based on homology models should be inter-
preted with caution, we note two results from the docking
computations: (1) docking computations were successful in
identifying the most active inhibitors (comparing to tested ana-
logs) for each of class A, B, and D compounds; and (2) the pre-
dicted order of class B compounds (for UT-A1 inhibition potency)
from computation agreed with experimental data. We did not
attempt to model UT-A1 versus UT-B selectivity because of
limitations of homology models.
DISCUSSION
A screening assay was implemented to identify small-molecule
UT-A1 inhibitors. Several classes of UT-A1 inhibitors werelsevier Ltd All rights reserved
Table 1. Structure-Activity Analysis of Urea Transport Inhibition
Class Inhibitor R1 R2 R3
UT-A1
IC50 (mM)
UT-B
IC50 (mM)
class A
8-hydroxyquinoline
UTA1inh-A1 piperidine Me 4-EtO-aniline 3.3 16
UTA1inh-A2 3-MeO-benzylamine H H 5.3 >50
UTA1inh-A3 thiomorpholine Me 4-MeO-aniline 3.5 6.2
UTA1inh-A4 piperidine Me 3-MeS-aniline 3.8 20
UTA1inh-A5 thiomorpholine Me 4-EtO-aniline 24 34
UTA1inh-A6 thiomorpholine Me 3-Cl,4-MeO-aniline 19 27
UTA1inh-A7 piperidine Me 3-Cl,4-Me-aniline 24 >50
UTA1inh-A8 piperidine Me 3-F,4-Me-aniline 25 >50
class B
aminothiazolone
UTA1inh-B1 O-ethyl acetate H H 3.7 4.8
UTA1inh-B2 OH OMe H 4.6 6.3
UTA1inh-B3 OMe OMe H 7.0 43
UTA1inh-B4 H OMe OH 25 6.2
class C
[1,3,5]-triazine
UTA1inh-C1 3,4-MeO-aniline 2-thio(4,5-dihydro-
thiazole)
3,4-MeO-aniline 4.2 >50
UTA1inh-C2 MeS 4-NH-Phenyl-
aniline
MeS 45 >50
UTA1inh-C3 3-MeO-aniline 4-Me-thiophenol 4-Me-aniline >50 42
class D
triazolothienopyrimidine
UTA1inh-D1 2,5-Me isopropyl 3.8 15
UTA1inh-D2 unsubstituted Me >50 35
UTA1inh-D3 4-Br thiophene >50 2.8
UTA1inh-D4 4-Et 3-MeO-propyl >50 28
Potency and selectivity of analogs from each of the four structural classes of urea transport inhibitors were examined.
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yielded multiple active compounds. Interestingly, analogs were
identified with high selectivity for inhibition of UT-A1 versus the
othermajor renal urea transporter, UT-B, as well as analogs lack-
ing selectivity. UT-A1 inhibition by all compoundswas reversible;
inhibition by class A, B, and C compounds was noncompetitive
with urea, whereas inhibition by class D compounds was
competitive. Functional studies, together with homology
modeling and docking computations, suggested inhibitor bind-
ing sites for class A and B compounds near the intracellular
urea pore region, and class C compounds near the extracellular
pore region.
The screening assay utilized an epithelial cell line with intrinsi-
cally low urea permeability that grew rapidly on uncoated plastic
and could be stably transfected to express UT-A1, AQP1, and
YFP-H148Q/V163S. The constitutive activity of UT-A1 withoutChemistry & Biology 20, 1235–1the need for cAMP agonists was advantageous for high-
throughput screening because it reduced assay complexity.
Transfection with AQP1 ensured that water permeability was
much greater than urea permeability, which avoided potentially
confounding compound effects on water permeability or cell vol-
ume, and which maximized the UT-A1-dependent difference in
kinetic signal. Transfection with YFP-H148Q/V163S allowed for
kinetic plate reader-based measurements of cell fluorescence,
which was related to cell volume because cell volume changes
alter cytoplasmic chloride concentration reciprocally, changing
YFP-H148Q/V163S fluorescence on a millisecond time-scale
(Galietta et al., 2001). The intrinsic cell fluorescence obviated
dye loading. A potential limitation of this assay is that YFP-
H148Q/V163S fluorescence is sensitive to chloride concentra-
tion and pH; however, UT-A1-dependent changes in cell
volume, which occur in seconds, are much faster than potential244, October 24, 2013 ª2013 Elsevier Ltd All rights reserved 1239
Figure 4. Selectivity and Structure-Activity Analysis of UT-A1 Inhibitors
(A) UT-B inhibition assay showing rapid dilution of acetamide-loaded rat erythrocytes in acetamide-free PBS, resulting in osmotic cell swelling after UT-B–
facilitated acetamide efflux and consequent cell shrinking. UT-B inhibition allows unopposed cell swelling and causes erythrocyte lysis.
(B) Concentration-inhibition data for inhibition of UT-A1 and UT-B for the four compounds from Figure 3 (mean ± SEM).
(C) Percentage of UT-B (y axis) and UT-A1 (x axis) inhibition for selected class A, B, C, and D compounds tested at 25 mM is shown.
(D) Structural determinants of unsubstituted 8-hydroxyquinolines (8-HQ) for UT-A1 inhibition activity (top). Structural determinants of aniline-substituted 8-HQ for
selective UT-A1 and dual UT-A1 and UT-B inhibition activities are shown (bottom).
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response to secondary changes in electrochemical driving
forces for chloride and proton transport. Notwithstanding this
caveat, the assay was robust, technically simple and inexpen-
sive, and successful in identifying small-molecule UT-A1
inhibitors.
Each of the four chemical classes has drug-like properties,
including the presence of multiple hydrogen bond acceptors, as
well as favorable molecular weight, aLogP, and topological polar
surface areas. The average molecular weights are 394, 343, 320,
and 458 for active class A, B, C, and D inhibitors, respectively;
average aLogP values are 4.6, 1.9, 4.8, and 3.8; and average
topological polar surface areas are 68.9, 110.8, 162.6, and
144.7 A˚2. The molecular weight and aLogP values are consistent
with the Lipinski guidelines for orally available drugs (Lipinski
et al., 2001). The topological polar surface areas are consistent
with the complementary guidelines for oral availability proposed
by Veber et al. (2002), with the exception of the class C com-
pounds, which are above the recommended cutoff of 140 A˚2.
There are several prior reports on the physio-chemical and
biological properties of the inhibitor scaffolds identified in this1240 Chemistry & Biology 20, 1235–1244, October 24, 2013 ª2013 Estudy. 8-Hydroxyquinolines (class A inhibitors) have been shown
to have antibacterial (Darby and Nathan, 2010) and anticancer
activities (Jiang et al., 2011). Clioquinol (5-chloro-7-iodo-8-
hydroxyquinoline) is an approved antifungal and antiprotozoal
agent. PBT2, an analog of clioquinol, has shown efficacy in a
transgenic mouse model of Alzheimer disease (Adlard et al.,
2008) and is in phase II clinical trials in humans (Lannfelt et al.,
2008, Faux et al., 2010). Although 8-hydroxyquinolines are
known metal-chelating compounds, some of the 8-alkoxyquino-
lines analogs studied here, which are unlikely to act as metal
chelators, had strong inhibition potency. Also, UTA1inh-A2
showed high UT-A1 selectivity over UT-B selectivity, suggesting
a specific inhibition mechanism. Aminothiazolones (class B
inhibitors) inhibit mushroom tyrosinase activity (Ha et al.,
2012) and protect the liver in a concanavalin A-induced injury
model (Luo et al., 2010). Dimeric aminothiazolone derivatives
inhibit CDC25 phosphatases, which are involved in cell
cycle progression and tumor development (Sarkis et al., 2012).
Aminothiazolones are structurally similar to rhodanines, which
are commonly identified from high-throughput screens, and
have been considered promiscuous (Baell and Holloway, 2010;lsevier Ltd All rights reserved
Figure 5. Characterization of UT-A1 Inhibitors
(A) Reversibility. Compounds were incubated (at 3 mM) with the triple transfected MDCK cells for 15 min, then washed twice and subjected to UT-A1 inhibition
assay.
(B) Urea competition. Concentration-inhibition data for UTA1inh-A1 using 800, 400, and 200-mM urea gradients are shown (left). Summary of IC50 as a function of
urea gradient is shown (right).
(C) Kinetics of UT-A1 inhibition. UT-A1 urea transport measured at different times after the addition of 3 mMUTA1inh-B1 or UTA1inh-C1 (left). Deduced time course
of percentage inhibition of UT-A1 urea transport (right).
(D) Transepithelial urea transport in MDCK cells stably expressing UT-A1. Cells were treated with 10 mM forskolin alone (black), forskolin + phloretin (0.7 mM)
(dashed thick black), and forskolin plus each of the indicated UT-A1 inhibitors at 30 mM (mean ± SEM).
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conclusion has been controversial because potent and selective
rhodanines are non-nucleoside inhibitors of hepatitis C NS5b
RNA polymerase (Powers et al., 2006), and rosiglitazone and
epalrestat, which are approved for antidiabetes and diabetic
neuropathy, respectively, contain heterocycles similar to rhoda-
nines and aminothiazolidones. Benzo-[1,3,5]-triazines (class C
inhibitors) have been reported to have anticancer and antioxi-
dant activities (Bekircan et al., 2005). Class D inhibitors are struc-
tural analogs of the triazolothienopyrimidine UTBinh-14 that we
previously reported as a UT-B-selective inhibitor (Anderson
et al., 2012). This general scaffold has antagonist activity against
5-HT6 receptors in vitro (Ivachtchenko et al., 2010). Synthesis of
each of the four inhibitor classes can be accomplished in a
modular manner, allowing diversification of the scaffold to
improve physicochemical properties for follow-up medicinal
chemistry.
UT-A1 inhibitors have a number of potential clinical indica-
tions. Urea transport inhibitors have a different mechanism of
action from conventional diuretics, which block salt transportChemistry & Biology 20, 1235–1across kidney tubule epithelial cells. Conventional diuretics
such as furosemide are used widely to increase renal salt and
water clearance in conditions associated with total body fluid
overload, including congestive heart failure, cirrhosis, and
nephrotic syndrome, as well in normovolemic states such as
hypertension and syndrome of inappropriate secretion of antidi-
uretic hormone. By disrupting countercurrent mechanisms and
intrarenal urea recycling, urea transport inhibitors, alone or in
combination with conventional diuretics, may induce a diuresis
in states of refractory edema where conventional diuretics
are ineffective. Potential indications of urearetics include
increasing solute clearance and free water excretion in states
of fluid overload and hypertension. We note that the efficacy of
urea transport inhibitors may be reduced in patients with low
plasma urea concentrations and low rates of urea excretion,
and when tubule function is impaired in acute or chronic renal
insufficiency.
In summary, four chemical classes of drug-like UT-A1 inhibi-
tors were identified, with analogs having a wide range of
UT-A1 versus UT-B selectivities. Functional studies and244, October 24, 2013 ª2013 Elsevier Ltd All rights reserved 1241
Figure 6. Computational Modeling of Urea
Transporter-Inhibitor Interaction
Putative inhibitor binding sites in rat UT-A1
deduced by functional measurements, homology
modeling, and computational docking are shown.
Zoomed-in and zoomed-out representations of
representations of UTA1inh-A1 (A) and UTA1inh-B1
(B) bound to the UT-A1 cytoplasmic domain; and
UTA1inh-C1 (C) bound to the extracellular domain.
Positions of putative urea binding sites deduced
from homology modeling are indicated.
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on the UT-A1 protein. Following optimization of pharmacological
properties, to include selectivity studies against renal solute
transporters, testing of inhibitors in rodent models of urinary
concentrating function, edema, and hypertension should be
informative on the role of UT-A1 in normal physiology and edema
states, and on the potential utility of UT-A1 inhibitors for drug
therapy.SIGNIFICANCE
Using a target-based screening assay, this study identified
small-molecule UT-A1-selective inhibitors. UT-A1 inhibitors
have applications in elucidating the physiological role of
urea transport in the urinary concentrating mechanism,
and are potential drug development candidates predicted
to have therapeutic efficacy as ‘‘urearetics’’ in states of re-
fractory edema, as in congestive heart failure and cirrhosis,
in which conventional salt transport-blocking diuretics such
as furosemide have limited efficacy. UT-A1 inhibitors would
be first-in-their class drugs that address an unmet need in
kidney drug therapy.EXPERIMENTAL PROCEDURES
Collection of Rat Blood
Whole blood was collected from 12- to 16-week-old (300–400 g) Wistar rats by
orbital puncture after subcutaneous injection of sodium heparin. Procedures
were approved by the Committee on Animal Research at the University of
California, San Francisco.
Cell Lines
MDCK cells stably transfected with rat UT-A1 (MDCK-UT-A1, Fro¨hlich et al.,
2006) were grown in Dulbecco’s modified Eagle medium (DMEM) containing
10% FBS, penicillin G (100 U/ml), streptomycin (100 mg/ml), and hygromycin
(500 mg/ml). The cells were cotransfected with yellow fluorescent protein
YFP-H148Q/V163S (Galietta et al., 2001) using Lipofectamine 2000 (Invi-
trogen, Carlsbad, CA) according to the manufacturer’s instructions. Cells
resistant to hygromycin (500 mg/ml) and G418 (600 mg/ml) were selected
by flow cytometry. The UT-A1/YFP-transfected cells were then transfected
with cDNA encoding AQP1 and selected with Zeocin (500 mg/ml). MDCK
cells were maintained in DMEM supplemented with 10% FBS, penicillin G
(100 U/ml) and streptomycin (100 mg/ml) at 37C, 5% CO2.1242 Chemistry & Biology 20, 1235–1244, October 24, 2013 ª2013 Elsevier Ltd All rights resImmunofluorescence
Transfected MDCK cells were seeded onto poly-
D-lysine-coated, 12-mm diameter coverslips and
fixed with 4% paraformaldehyde for 15 min. After
blocking and permeabilization with 1% BSA and0.1% Triton X-100 for 30 min, coverslips were incubated with mouse anti-
AQP1 (1:100, Santa Cruz Biotechnology, Santa Cruz, CA) and rabbit anti-
UT-A1 (1: 1,000; LifeSpan BioSciences, Seattle, WA) for 2 hr. Cells were
then rinsed extensively with PBS and incubated for 60minwith 4 mg/ml donkey
anti-mouse IgG-conjugated Alexa Fluor 555 and goat anti-rabbit IgG-conju-
gated Alexa Fluor 647 (Invitrogen, Carlsbad, CA). Cells were imaged using a
laser scanning confocal microscope D-Eclipse C1 (Nikon) equipped with a Ni-
kon 1003, NA 1.49 Apo lens.
UT-A1 Inhibitor Identification by High-Throughput Screening
Primary screening was done using a collection of 90,320 diverse, drug-like
compounds from ChemDiv (San Diego, CA). For analysis of structure-activity
relationships, >400 commercially available analogs (ChemDiv and Asinex)
were tested. Cells were plated into black 96-well microplates with clear plastic
bottoms (Corning-Costar 3904) at 15,000 cells/well and cultured for 24 hr at
37C before assay. Microplates containing cultured cells were washed twice
with PBS and 150 ml of test compound (25 mM final) was added and incubated
at 37C, 90% humidity, 5% CO2 for 15 min. Eighty wells contained test com-
pounds, and the first and last columns of each plate were used for negative (no
test compound) and positive (0.35 mM phloretin) controls. Assays were done
on a plate reader (Tecan Trading AG, Switzerland) equipped with custom YFP
filter set. Each assay consisted of a continuous 15 s read (5 Hz) with 50 ml of
3.2 M urea in PBS injected at 1 s (at 130 ml/sec) to give a 800 mM final urea
gradient. Initial rates of urea influx were computed using a model of cell
shrinking-swelling described previously (Levin et al., 2007) and analyzed using
GraphPad Prism, version 5.01.
Functional Characterization of UT-A1 Inhibitors
Reversibility of UT-A1 inhibition was tested by pre-incubating MDCK cells
(expressing YFP-H148Q/V163S, AQP1 and UT-A1) with inhibitors for 15 min
(at 3 mM) and then washing with PBS prior to assay. The urea concentration
dependence of UT-A1 inhibition was studied from inhibitor concentration-
response data (0.3–60 mM) using different of urea gradients (200–1,600 mM).
The kinetics of UT-A1 inhibition was measured by adding inhibitors (3 mM) at
different times prior to assay.
UT-B Inhibition Measurements
Whole rat blood was diluted to a hematocrit of 1.5% in PBS containing
1.25 M acetamide and 5 mM glucose. One hundred microliters of the erythro-
cyte suspension was added to each well of a 96-well round-bottommicroplate
to which test compounds were added. After 15 min incubation, 20 ml of the
erythrocyte suspension was added rapidly to each well of a 96-well black-
walled plate containing 180 ml PBS containing 1% DMSO. Vigorous mixing
was achieved by repeated pipetting. Erythrocyte lysis was quantified by
absorbance at a 710-nm wavelength. No-lysis controls (isotonic buffer;
PBS plus 1.25 M acetamide with 1% DMSO) and full-lysis controls (distilled
H2O) were done in all plates. Percentage erythrocyte lysis was computederved
Chemistry & Biology
Small-Molecule UT-A Inhibitorsas: % lysis = 100% (Aneg Atest)/(Aneg Apos), where A are absorbance values
at 710 nm.
Transepithelial Transport Measurements
MDCK-UT-A1 cells were grown on 12-mm diameter collagen-coated Trans-
well inserts (0.4 mm pore size; Costar) as described (Levin et al., 2007). Inserts
were loaded with 23 105 cells/cm2 and cultured for 4 days to form tight mono-
layers with transepithelial resistance 500–600 U cm2. Urea flux in the basolat-
eral-to-apical direction was measured in response to a 15 mM urea gradient.
Measurements were done in 12-well plates in which PBS, containing either
DMSO vehicle or forskolin (10 mM), with or without UT-A1 inhibitor, was added
to both the apical-facing (0.2 ml) and basal-facing (1 ml) surfaces. Cultures
were incubated for 30 min at 37C, and then the basal-facing solution was
replaced by PBS (containing the same components) plus 15 mM urea.
Samples (5 ml) of apical fluid were collected at specified times for urea assay
(Quantichrom Urea Assay Kit, BioAssay Systems, Hayward, CA). Inhibition
was computed as % inhibition = 100%$(Aforsk-Atest)/ (Aforsk-Aphlor). Aforsk and
Aphlor are absorbance (at 520 nm) for cultures treated with forskolin and
forskolin + phloretin, respectively, and Atest from cultures treated with
forskolin + test compound.
Homology Modeling and Docking Computations
A homology model of UT-A1 was generated using the SWISS MODEL
online utility (http://swissmodel.expasy.org) in automated mode, using the
sequence of the full rat UT-A1 protein (accession code, NP_062220.2). The
model was generated using coordinates from the X-ray crystal structure of
bovine UT-B (PDB 4EZC, solved to 2.5 A˚; Levin et al., 2012) as a homology
template. Two structural models were generated, comprising residues
105–449 (65.2% identity with bovine UT-B) and 568–909 of UT-A1 (67.5%
sequence identity with bovine UT-B). Due to the slightly improved sequence
identity, the latter model was used for docking computations. Because the
UT-B structure was solved as a trimer of identical structures, the homology
model was also generated in this format, and a single structure of the UT-A1
model was isolated for docking computations. The homology model of
UT-A1 was prepared for docking using the FRED-RECEPTOR utility (OpenEye
Scientific, Santa Fe, NM), with cytoplasmic and extracellular domains
defined with 10 cubic A˚ boxes. Structures of class A, B, and C inhibitors
were drawn in ChemDraw (Cambridge Software, Cambridge, MA), converted
to SMILES strings, transformed to three-dimensional conformations, and
minimized using PIPELINE PILOT (Accelrys, San Diego, CA). The single con-
formations were passed through MOLCHARGE (OpenEye Scientific,
Santa Fe, NM) to apply MMFF charges, and through OMEGA (OpenEye
Scientific) to generate multiconformational libraries. The inhibitor conforma-
tional libraries were docked using FRED (v2.2.5; OpenEye Scientific),
which was configured to use consensus scoring functions ChemGauss3,
ChemScore, OEChemScore, ScreenScore, ShapeGauss, PLP, and ZapBind.
Docking of the inhibitors was carried out free of pharmacophore restraint.
The final protein-inhibitor complexes were visualized using PYMOL (Schro¨-
dinger, San Diego, CA).
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